A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Eisai

Status: Completed

Conditions: Carcinoma, Hepatocellular; Neoplasms; Neoplasms, Glandular and Epithelial; Carcinoma

Treatments: Drug: Lenvatinib

Study type: Observational

Funder types: Industry

Identifiers

NCT04008082

LEN03T (Other Identifier)

E7080-M081-510

Details and patient eligibility

About

The primary purpose of this study to continue follow-up of participants enrolled in the study E7080-M081-504 (NCT03663114) of lenvima capsules and to evaluate the overall survival of participants with hepatocellular carcinoma.

Enrollment: 412 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All participants enrolled in the study E7080-M081-504 with informed consent to participate in this study.

Exclusion criteria

• Participants who do not have unresectable hepatocellular carcinoma
• Participants who have not given informed consent or have withdrawn consent to participation
• Participants with a history of hypersensitivity to any ingredient of lenvima
• Pregnant or possibly pregnant women
• Participants previously treated with lenvima (excluding those previously enrolled in the Study E7080-M081-504 [NCT03663114] at another clinical site).

Trial design

412 participants in 1 patient group

Lenvatinib

Description:

Lenvatinib capsules 12 milligram (mg) for participants with body weight greater than or equal to (\>=) 60 kilograms (kg) or 8 mg for participants with body weight less than (\<) 60 kg, orally, once daily as per routine clinical practice.

Treatment:

Drug: Lenvatinib